Insights
Insights on health, access and innovation
Read practical thinking from Newmarket Strategy on the policy, access, reimbursement and health system issues shaping healthcare and life sciences.
NHS pharmaceuticals negotiator to join Newmarket Strategy
Health and life sciences consultancy, Newmarket Strategy, has added another NHS and government leader to its top team. Robert Kettell, currently the NHS’s Director of Medicines Negotiation, will join Newmarket as…
The Future of Healthcare and Life Sciences Research Conference 2025
The Future of Life Sciences event brought together leaders from across the NHS, government, academia, and industry to tackle one of the UK’s greatest opportunities—and challenges: unlocking the full potential of…
The value of commercial clinical trials
One of the main messages outlined in the ‘Lord O’Shaughnessy review on commercial clinical trials’ was the economic and financial value to the UK. The review’s own research showed that…
What does the new integrated rules-based med-tech pathway mean?
NHS England and NICE have published a consultation document which sets out proposals to move towards a more rules-based, integrated, and predictable pathway for the evaluation, funding, and commissioning of medical…
What does the General Election mean for UK Health and Life sciences
Prime Minister Rishi Sunak wrong-footed political commentators and analysts yesterday by calling a General Election on the 4th of July. The decision looks to have been driven by better economic indicators…
Is the NHS finally developing a clear evaluation and reimbursement pathway for digital health technologies?
Today the National Institute for Health and Care Research (NIHR) in collaboration with the Office for Life Sciences (OLS) and the National Institute for Health and Care Excellence (NICE), opened a…
Events
